Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis

• Published in: Farmakoèkonomika (Moskva. Online) Vol. 12; no. 4; pp. 255 - 266
• Main Authors: Sarvilina, I. V., Galustyan, A. N., Hadzhidis, A. K., Sardaryan, I. S., Lavrov, N. V., Gromova, O. A., Prokofieva, Yu. S.
• Format: Journal Article
• Language: English; Russian
• Published: IRBIS LLC 18.02.2020
• Subjects: chondroguard; chondroitin sulfate; cost-effectiveness; сlinical and economic analysis
• ISSN: 2070-4909; 2070-4933
• DOI: 10.17749/2070-4909.2019.12.4.255-266

Aim: to conduct a comparative clinical and economic analysis of using three SYSADOA drugs containing chondroitin sulfate or modifying its biosynthesis in patients with stage II knee osteoarthritis in an outpatient setting.Material and methods. This was a retrospective comparative study, with the inclusion of data from medical records of outpatients with stage II knee arthritis according to the Kellgren & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment efficiency based on the dynamics of pain, functional ability of the joint according to the Lequesne index, as well as the VAS index, the WOMAC index, ultrasound results and quality of life according to the EuroQol-5D questionnaire. The medical records of patients (n = 90) with stage II knee osteoarthritis are systematized according to inclusion / exclusion criteria. All patients were divided into 3 groups: group 1 (n = 30) received chondroitin sulfate, 100 mg in 1 ml (Chondroguard® , Sotex, Russia), i /m, every other day, the first 3 injections of 100 mg each with good tolerance starting from the 4th injection of 200 mg, the course of treatment was 25 injections over 50 days; group 2 (n = 30) received an active substance-glycosaminoglycan-peptide complex (Romania), on the 1st day – 0.3 ml, on the 2nd day – 0.5 ml and then 3 times a week for 1 ml, the course of treatment – 20 injections per 44 days; group 3 (n = 30) received the active substance – bioactive concentrate from small sea fish (Romania), 1 ml per day, course of treatment – 20 injections, 20 days.Results. It is shown that the treatment of stage II osteoarthritis of the knee with Chondroguard® is the most economically feasible in terms of the cost-effectiveness ratio (CER=9182).Conclusion. The study results are recommended for decision making on the use of SYSADOA at the level of doctors and health care providers.